Previous 10 | Next 10 |
home / stock / pcsa / pcsa articles
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling over 50 points on Friday The Dow traded up 0.05% to 38,069.66...
Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but is...
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 100 points on Friday. The Dow traded up 0.32% to 38,170.95 ...
U.S. stocks ended in the green on Thursday with the Nasdaq rising 0.2% to 15,510.50 and the S&P 500 up 0.5% at 4,894.16. The Dow Jones Industri...
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.25% to 37,900.45 while...
Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2...
U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday. The Dow traded up 0.06% to 37...
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) shares are soaring Thursday after the company announced the completion of the safety tolerability eval...
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 100 points on Thursday. Following the market opening Thursday, the Do...
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa Pharmaceuticals Inc. Website:
Processa (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial. The...
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses (PR) and one stable disease (SD) For all NGC-Cap doses, 5-Fluorouracil (5-FU) exp...
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, will be represented at this month’s EF Hutton Annual Global Conference. According to the announcement, ke...